{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:03:11Z","timestamp":1780117391929,"version":"3.54.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100022963","name":"Key Research and Development Program of Zhejiang Province","doi-asserted-by":"publisher","award":["2023C03031"],"award-info":[{"award-number":["2023C03031"]}],"id":[{"id":"10.13039\/100022963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32370679"],"award-info":[{"award-number":["32370679"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92581118"],"award-info":[{"award-number":["92581118"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key Research and Development Program for Active Health and Aging Response","award":["2023YFC3604000"],"award-info":[{"award-number":["2023YFC3604000"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12325-026-03571-x","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:04:58Z","timestamp":1774944298000},"page":"2580-2592","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety, Tolerability and PK Characteristics of RM301B Eye Drops: A Single-Centre, Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Phase I Clinical Trial"],"prefix":"10.1007","volume":"43","clinical-trial-number":[{"clinical-trial-number":"chictr2500111837","registry":"10.18810\/chictr"}],"author":[{"given":"Zhishu","family":"Bao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixiang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangde","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8391-3806","authenticated-orcid":false,"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"issue":"13","key":"3571_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13133950","volume":"13","author":"M Lendzioszek","year":"2024","unstructured":"Lendzioszek M, Bryl A, Poppe E, Zorena K, Mrugacz M. Retinal vein occlusion\u2013background knowledge and foreground knowledge prospects\u2014a review. J Clin Med. 2024;13(13):3950.","journal-title":"J Clin Med"},{"issue":"1","key":"3571_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00661-7","volume":"8","author":"JX Li","year":"2023","unstructured":"Li JX, Wang YH, Bair H, et al. Risk assessment of retinal vascular occlusion after COVID-19 vaccination. NPJ Vaccines. 2023;8(1):64.","journal-title":"NPJ Vaccines"},{"key":"3571_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2021.100964","volume":"85","author":"SS Hayreh","year":"2021","unstructured":"Hayreh SS. Photocoagulation for retinal vein occlusion. Prog Retin Eye Res. 2021;85:100964.","journal-title":"Prog Retin Eye Res"},{"issue":"4","key":"3571_CR4","doi-asserted-by":"publisher","first-page":"P303","DOI":"10.1016\/j.ophtha.2024.12.025","volume":"132","author":"JL Kovach","year":"2025","unstructured":"Kovach JL, Bailey ST, Kim SJ, et al. Retinal vein occlusions preferred practice pattern\u00ae. Ophthalmology. 2025;132(4):P303\u201343.","journal-title":"Ophthalmology"},{"issue":"22","key":"3571_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10225300","volume":"10","author":"A Grzybowski","year":"2021","unstructured":"Grzybowski A, Markeviciute A, Zemaitiene R. Treatment of macular edema in vascular retinal diseases: a 2021 update. J Clin Med. 2021;10(22):5300.","journal-title":"J Clin Med"},{"issue":"10","key":"3571_CR6","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.4103\/ijo.IJO_1866_19","volume":"68","author":"A Kelkar","year":"2020","unstructured":"Kelkar A, Webers C, Shetty R, et al. Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema. Indian J Ophthalmol. 2020;68(10):2143\u20137.","journal-title":"Indian J Ophthalmol"},{"issue":"3","key":"3571_CR7","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1007\/s13346-020-00843-z","volume":"11","author":"SA Gaballa","year":"2021","unstructured":"Gaballa SA, Kompella UB, Elgarhy O, et al. Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives. Drug Deliv Transl Res. 2021;11(3):866\u201393.","journal-title":"Drug Deliv Transl Res"},{"issue":"7","key":"3571_CR8","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s00417-016-3350-x","volume":"254","author":"JG Garweg","year":"2016","unstructured":"Garweg JG, Zandi S. Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex\u00ae) in its treatment. Graefes Arch Clin Exp Ophthalmol. 2016;254(7):1257\u201365.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"3571_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12030269","volume":"12","author":"R Varela-Fern\u00e1ndez","year":"2020","unstructured":"Varela-Fern\u00e1ndez R, D\u00edaz-Tom\u00e9 V, Luaces-Rodr\u00edguez A, et al. Drug delivery to the posterior segment of the eye: biopharmaceutic and pharmacokinetic considerations. Pharmaceutics. 2020;12(3):269.","journal-title":"Pharmaceutics"},{"issue":"3","key":"3571_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/ICU.0000000000000850","volume":"33","author":"D Patel","year":"2022","unstructured":"Patel D, Patel SN, Chaudhary V, Garg SJ. Complications of intravitreal injections: 2022. Curr Opin Ophthalmol. 2022;33(3):137\u201346.","journal-title":"Curr Opin Ophthalmol"},{"issue":"1","key":"3571_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/aos.15215","volume":"101","author":"E Stefansson","year":"2023","unstructured":"Stefansson E, Loftsson T, Larsen M, et al. Topical treatment of diabetic macular edema using dexamethasone ophthalmic suspension: a randomized, double-masked, vehicle-controlled study. Acta Ophthalmol. 2023;101(1):22\u201333.","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"3571_CR12","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/bcp.13502","volume":"84","author":"T Zimmermann","year":"2018","unstructured":"Zimmermann T, H\u00f6chel J, Becka M, et al. Topical administration of regorafenib eye drops: phase I dose-escalation study in healthy volunteers. Br J Clin Pharmacol. 2018;84(5):865\u201375.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"3571_CR13","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1016\/S2352-3026(20)30368-9","volume":"8","author":"J Halton","year":"2021","unstructured":"Halton J, Brand\u00e3o LR, Luciani M, et al. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b\/3, non-inferiority trial. Lancet Haematol. 2021;8(1):e22\u201333.","journal-title":"Lancet Haematol"},{"key":"3571_CR14","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/978-1-62703-050-2_16","volume":"929","author":"J Gabrielsson","year":"2012","unstructured":"Gabrielsson J, Weiner D. Non-compartmental analysis. Methods Mol Biol. 2012;929:377\u201389.","journal-title":"Methods Mol Biol"},{"issue":"17","key":"3571_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14171983","volume":"14","author":"MR Munk","year":"2024","unstructured":"Munk MR, Ceklic L, Stillenmunkes R, et al. Integrated assessment of OCT, multimodal imaging, and cytokine markers for predicting treatment responses in retinal vein occlusion associated macular edema: a comparative review of anti-VEGF and steroid therapies. Diagnostics. 2024;14(17):1983.","journal-title":"Diagnostics"},{"issue":"12","key":"3571_CR16","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1136\/bjophthalmol-2020-317337","volume":"105","author":"T Ciulla","year":"2021","unstructured":"Ciulla T, Pollack JS, Williams DF. Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15,613 patient eyes. Br J Ophthalmol. 2021;105(12):1696\u2013704.","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"3571_CR17","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1136\/bjo-2022-323120","volume":"108","author":"RB Bhisitkul","year":"2024","unstructured":"Bhisitkul RB, Campochiaro PA, Blotner S, Quezada-Ruiz C, Liu M, Haskova Z. Heterogeneity in disease activity, frequency of treatments, and visual outcomes among patients with retinal vein occlusion: relationship between injection need and vision with as-needed ranibizumab. Br J Ophthalmol. 2024;108(9):1216\u201325.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"3571_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13010105","volume":"13","author":"D-M Darabu\u015f","year":"2025","unstructured":"Darabu\u015f D-M, D\u0103r\u0103bu\u015f RG, Munteanu M. The diagnosis and treatment of branch retinal vein occlusions: an update. Biomedicines. 2025;13(1):105.","journal-title":"Biomedicines"},{"key":"3571_CR19","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ajo.2016.04.020","volume":"169","author":"H Hoerauf","year":"2016","unstructured":"Hoerauf H, Feltgen N, Weiss C, et al. Clinical efficacy and safety of ranibizumab versus dexamethasone for central retinal vein occlusion (COMRADE-C): a European label study. Am J Ophthalmol. 2016;169:258\u201367.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"3571_CR20","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1111\/aos.13381","volume":"96","author":"LO Hattenbach","year":"2018","unstructured":"Hattenbach LO, Feltgen N, Bertelmann T, et al. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmol. 2018;96(1):e10\u20138.","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"3571_CR21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1167\/iovs.10-5285","volume":"52","author":"JE Chang-Lin","year":"2011","unstructured":"Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52(1):80\u20136.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3571_CR22","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.2147\/OPTH.S209395","volume":"16","author":"K Kishore","year":"2022","unstructured":"Kishore K, Bhat PV, Venkatesh P, Canizela CC. Dexamethasone intravitreal implant for the treatment of macular edema and uveitis: a comprehensive narrative review. Clin Ophthalmol. 2022;16:1019\u201345.","journal-title":"Clin Ophthalmol"},{"key":"3571_CR23","volume":"11","author":"J Coelho","year":"2019","unstructured":"Coelho J, Pessoa B, Meireles A. Long-term management of non-ischemic central retinal vein occlusion with fluocinolone acetonide intravitreal implant 190 \u03bcg (ILUVIEN\u00ae). Ther Adv Ophthalmol. 2019;11:2515841418820755.","journal-title":"Ther Adv Ophthalmol"},{"key":"3571_CR24","doi-asserted-by":"publisher","first-page":"961","DOI":"10.2147\/DDDT.S403259","volume":"17","author":"Y Mushtaq","year":"2023","unstructured":"Mushtaq Y, Mushtaq MM, Gatzioufas Z, Ripa M, Motta L, Panos GD. Intravitreal fluocinolone acetonide implant (ILUVIEN(\u00ae)) for the treatment of retinal conditions. a review of clinical studies. Drug Des Devel Ther. 2023;17:961\u201375.","journal-title":"Drug Des Devel Ther"},{"issue":"7","key":"3571_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0305573","volume":"19","author":"HX Tang","year":"2024","unstructured":"Tang HX, Li JJ, Yuan Y, Ling Y, Mei Z, Zou H. Comparing the efficacy of dexamethasone implant and anti-VEGF for the treatment of macular edema: a systematic review and meta-analysis. PLoS ONE. 2024;19(7):e0305573.","journal-title":"PLoS ONE"},{"issue":"7","key":"3571_CR26","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.oret.2020.09.024","volume":"5","author":"MS Ramos","year":"2021","unstructured":"Ramos MS, Xu LT, Singuri S, et al. Patient-reported complications after intravitreal injection and their predictive factors. Ophthalmol Retina. 2021;5(7):625\u201332.","journal-title":"Ophthalmol Retina"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03571-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03571-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03571-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:51:32Z","timestamp":1780116692000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03571-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3571"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03571-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Zhishu Bao, Wendan Xu, Ruoyu Li, Haihui Wei, Qing Dong, Ziang Xu, Linlin Li, Chenglong Li, Huixiang Ma, Jia Qu, Liangde Xu, and Hong Wang declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This research adheres to the protocols and consensus ethical principles of the Declaration of Helsinki, the International Ethical Guidelines of the Council for International Organizations of Medical Sciences, applicable ICH E6 guidelines, and relevant laws and regulations at the research centre. It was approved by the Ethics Committee of the Eye Hospital of Wenzhou Medical University (2024-053-Y-05).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}